ArticleNeurology2009
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
Charles L Howe et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
11 papers cite it
this papercites it
ArticleNeurology2009
Charles L Howe et al.PubMed ↗Publisher ↗
No numbers read from the abstract.